LCGC North America
Get the most from your method by considering what you want it to do and setting appropriate chromatographic parameters.
Ultimately we need sensitive, reproducible, and robust chromatographic results that are fit for purpose, according to our analytical requirements. Having chromatographic performance targets to work toward will not only result in more robust chromatography, but they will be a great indicator of when you are heading down the wrong development path, or when there are underlying problems with the method or equipment.
There are many regulatory organizations that have set analytical method performance requirements. For the purposes of this discussion we will refer to the current United States Food and Drug Administration (FDA) values for the validation of chromatographic methods (1,2).
Retention factors (k) of 2–10 are commonly used (with the FDA stipulating k ≥ 2) but this may not work for all analyses. If k < 1 separations will be less stable and reproducible, exhibit greater susceptibility to chromatographic interferences at the beginning of the chromatogram (that is, peaks poorly resolved from unretained material at the column dead time t0), and retention of analytes with low k values will be more sensitive to small changes in mobile-phase composition. A k value of 1–2 may work well when faster chromatography is desired, where samples do not contain a lot of endogenous or matrix components, or where pH or buffer strength are not vital in controlling retention or selectivity. For complex mixtures, k values greater than 10 may be needed to resolve all peaks, however be aware of peak broadening of later-eluted peaks that may reduce resolution.
Efficiency can be increased by increasing column length, reducing internal diameter, or decreasing the particle size. It is better to use a smaller diameter packing than to increase the column length, which will increase analysis time. However, a decrease in particle size will result in an increase in system back pressure. The use of smaller particles and narrower column internal diameters both require minimized extracolumn dead volume to avoid efficiency losses. The FDA stipulates that the value for N should be >2000, which is typically easily achieved with modern high performance liquid chromatography (HPLC) columns.
Tailing peaks create issues with resolution, quantitation, and reproducibility. Peak shape is often the controlling factor when optimizing complex separations, especially when components are present in very different concentrations. Peak tailing can be minimized by using type II or III silica, minimizing system volumes, using the correct connections and fittings, employing the correct buffer type and strength, and by optimizing the sample diluent. A value within the recommended range (tailing factor TF ≤ 2) may not always be ideal and may need further optimization. For example, the analysis of a stability indicating sample at different buffer concentrations demonstrates the importance of the tailing factor. At a lower buffer concentration (13.4 mM) the degradant peak in the sample has a relatively high tailing factor of 1.72, which although it is in the FDA recommended range, results in poor resolution (Rs = 0.98) between the degradant and the preceding peak. Increasing the buffer concentration to 23.6 mM not only improves the peak tailing of the degradant peak (TF = 1.43), but also results in resolution of the two peaks (Rs = 1.69).
Injection precision is important for reproducible chromatographic results and should be estimated in the same way for each analysis. It is indicative of performance of the plumbing, column, and environmental conditions at the time of analysis. Assessment of injection reproducibility can be used to aid in the diagnosis of potential system problems such as leaks. It is expressed as relative standard deviation (RSD) and is measured by multiple injections of a homogeneous sample (RSD <1% for n ≥ 5). The injection precision of modern autosamplers is 0.15–0.9%, depending on the sample volume. Several factors that affect precision should be considered to minimize errors, such as pH, buffer type, sample degradation, mobile-phase stability, sample adsorption, accurate dilutions, homogeneous sampling, and the use of an internal standard to estimate loss during sample preparation.
Before setting a value for resolution it is important to ask a couple of questions that relate to the specific separation first. For example, what value is acceptable? What value is required for reliable quantitation? Resolution is a function of retention (k), selectivity (α), and efficiency (N), which can all be modified to improve resolution. Rs > 1.5 can often be easily obtained for samples containing five or less components; however, for complex mixtures Rs > 1.8 is required for rugged performance. “Real world” setting of resolution specifications requires experience in HPLC and the method under consideration. Although values of Rs > 2 are recommended, sometimes it is not practical with very complex samples or depending on the type or stage of analysis. The early-stage analysis of pharmaceutical impurities may be carried out successfully with a minimum Rs value of 1.2 to give reliable, reproducible quantitation of all impurities. Conversely, late-stage pharmaceutical impurity analyses require much more stringent Rs values (>4) to give reliable quantitation of impurities.
2024 EAS Awardees Showcase Innovative Research in Analytical Science
November 20th 2024Scientists from the Massachusetts Institute of Technology, the University of Washington, and other leading institutions took the stage at the Eastern Analytical Symposium to accept awards and share insights into their research.
Inside the Laboratory: The Richardson Group at the University of South Carolina
November 20th 2024In this edition of “Inside the Laboratory,” Susan Richardson of the University of South Carolina discusses her laboratory’s work with using electron ionization and chemical ionization with gas chromatography–mass spectrometry (GC–MS) to detect DBPs in complex environmental matrices, and how her work advances environmental analysis.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
Infographic: Be confidently audit ready, at any time and reduce failures in pharma QC testing
November 20th 2024Discover how you can simplify the audit preparation process with data integrity dashboards that provide transparency to key actions, and seamlessly track long-term trends and patterns, helping to prevent system suitability failures before they occur with waters_connect Data Intelligence software.
Critical Role of Oligonucleotides in Drug Development Highlighted at EAS Session
November 19th 2024A Monday session at the Eastern Analytical Symposium, sponsored by the Chinese American Chromatography Association, explored key challenges and solutions for achieving more sensitive oligonucleotide analysis.